Overview
Bipolar disorder caused by drug, also known as substance-induced bipolar disorder, is a condition characterized by mood disturbances that are directly attributable to the physiological effects of a substance or medication 14. These substances can include illicit drugs, prescribed medications, or even toxins 14.Diagnosis
Diagnosis requires evidence of mood symptoms consistent with mania or depression that develop during or shortly after substance intoxication or withdrawal, or after exposure to a medication 4.
The mood disturbance must be sufficiently severe to warrant clinical attention 4.
The disturbance is not better explained by another mental disorder 4.
The disturbance does not occur exclusively during the course of delirium 4.Management
Acute Mania: Pharmacological treatments for acute mania include olanzapine, paliperidone, quetiapine, ziprasidone, risperidone, divalproex, and haloperidol, which have shown better tolerability compared to placebo 1. Tamoxifen and tamoxifen plus lithium or valproate demonstrated the highest clinical efficacy in acute mania 1. Other agents with efficacy in acute mania compared to placebo include aripiprazole, asenapine, carbamazepine, cariprazine, lithium, and valproate 6.
Bipolar Depression: Atypical antipsychotics (AAPs) such as cariprazine, lumateperone, lurasidone, olanzapine, and quetiapine are FDA-approved for bipolar depression 3. All studied AAPs were more efficacious than placebo for response rate 3. Cariprazine, lurasidone, olanzapine, and quetiapine showed higher remission rates than placebo 3. Agomelatine has shown promising efficacy and tolerability in treating bipolar depression, with response rates ranging from 43% to 91% within 6-12 weeks 2.
Maintenance Phase: Treatments for the maintenance phase include various antipsychotics and mood stabilizers. Aripiprazole plus valproate, lamotrigine, and lamotrigine plus valproate showed efficacy in preventing recurrence/relapse of any mood episode 9.Special Populations
Genetic Factors: The s allele of the SLC6A4 5-HTTLPR polymorphism has a nominally significant association with antidepressant-associated treatment-emergent mania (TEM) 4. Research is ongoing to identify genetic polymorphisms associated with bipolar disorder comorbid with substance use disorder 7.Key Recommendations
For acute mania, medications such as olanzapine, paliperidone, quetiapine, ziprasidone, risperidone, divalproex, and haloperidol are better tolerated than placebo 1. (Evidence: Strong)
In bipolar depression, atypical antipsychotics including cariprazine, lumateperone, lurasidone, olanzapine, and quetiapine are more efficacious than placebo for response and remission rates 3. (Evidence: Strong)
Agomelatine shows promise for treating bipolar depression, demonstrating significant efficacy and good tolerability without an obvious risk of inducing mood switching 2. (Evidence: Moderate)References
1 Huang W, He S, Liu M, Xu J. Comparative efficacy, safety, and tolerability of pharmacotherapies for acute mania in adults: a systematic review and network meta-analysis of randomized controlled trials. Molecular psychiatry 2025. link
2 Li J, Luo H, Luo Q. Agomelatine bears promising potential in treating bipolar depression- a systematic review. International journal of psychiatry in clinical practice 2024. link
3 Li S, Xu C, Hu S, Lai J. Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis. European psychiatry : the journal of the Association of European Psychiatrists 2024. link
4 Nuñez NA, Coombes BJ, Melhuish Beaupre L, Romo-Nava F, Gardea-Resendez M, Ozerdem A et al.. Antidepressant-Associated Treatment Emergent Mania: A Meta-Analysis to Guide Risk Modeling Pharmacogenomic Targets of Potential Clinical Value. Journal of clinical psychopharmacology 2023. link
5 Hong JSW, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM et al.. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. Molecular psychiatry 2022. link
6 Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Nomura I et al.. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Molecular psychiatry 2022. link
7 de Marco A, Scozia G, Manfredi L, Conversi D. A Systematic Review of Genetic Polymorphisms Associated with Bipolar Disorder Comorbid to Substance Abuse. Genes 2022. link
8 Hesam-Shariati S, Overs BJ, Roberts G, Toma C, Watkeys OJ, Green MJ et al.. Epigenetic signatures relating to disease-associated genotypic burden in familial risk of bipolar disorder. Translational psychiatry 2022. link
9 Kishi T, Ikuta T, Matsuda Y, Sakuma K, Okuya M, Mishima K et al.. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Molecular psychiatry 2021. link